Semaglutide

Semaglutide is a molecule used in drugs like Wegovy and Ozempic, manufactured by Novo Nordisk, primarily for weight loss and type 2 diabetes treatment. It's newsworthy due to several recent developments. Firstly, the patent on semaglutide is expiring in India, potentially leading to cheaper, generic versions and reshaping the global obesity treatment landscape. Secondly, alternative GLP-1 medications, such as orforglipron by Eli Lilly, are being developed as oral alternatives, showing promising results in clinical trials. Finally, UK regulators have issued warnings regarding a small risk of severe acute pancreatitis associated with GLP-1 medications like semaglutide. This highlights the increasing prevalence and scrutiny of these drugs, with millions using them for weight loss, and underscores the need for awareness of potential side effects and the ongoing development of new formulations.